Sam Altman-backed Retro Biosciences is widening its Alzheimer’s trial after early doses showed no red flags. Most drug trials ...
New MOU pairs GlycanAge’s glycan-based biological age test with ExoEarth’s exosome platform, bringing inflammaging testing ...
APLMS will use Singapore, China and India to test how longevity science can translate into function, prevention and healthier ...
A 350-patient study finds a palm-sized ECG device spots dangerous heart rhythms that hospital-grade monitors miss entirely.
Obesity biotech aims to reduce fat while preserving lean mass, with first-in-human studies planned for late 2027.
Aesthetics empire opens its first wellness clinic, and it says something about where precision longevity in Southeast Asia is ...
Prevention gets tech budget it deserves as a $499, hour-long body scan backed by Zuckerberg and Sharapova lands in SoHo.
Leisure exercise lowers dementia risk, while physically demanding jobs may raise it – twist that reshapes how we think about ...
New $1.08m grant aimed at the immune biology behind stem cell transplants, a research problem getting more urgent as more ...
Researchers say disrupted sleep may be one of the earliest signs of Alzheimer’s, arriving years before memory loss and ...
NeuLogiq platform earned high marks from ALS and FTD patients using it at home, addressing a gap left by motor-only rating ...
Facing a legal challenge to its sleep-tracking claims, Oura is publishing the science behind its ring, with real stakes for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results